Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript
09:16pm, Thursday, 30'th Oct 2025
Biogen Inc. ( BIIB ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Tim Power - Head of Investor Relations Christopher Viehbacher - President, CEO & Director Priya Singhal - E
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View
03:06pm, Thursday, 30'th Oct 2025
Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.
Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
10:31am, Thursday, 30'th Oct 2025
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compar
Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates
08:16am, Thursday, 30'th Oct 2025
Biogen Inc. (BIIB) came out with quarterly earnings of $4.81 per share, beating the Zacks Consensus Estimate of $3.89 per share. This compares to earnings of $4.08 per share a year ago.
Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise
07:40am, Thursday, 30'th Oct 2025
Biogen cut its full-year adjusted-earnings expectations, though third-quarter profit rose on strength from its Alzheimer's drug and rare-disease treatments.
Biogen trims annual profit forecast on expected hit from R&D-related charges
06:11am, Thursday, 30'th Oct 2025
Biogen cut its annual profit forecast on Thursday, as it expects to take a hit of $1.25 per share from R&D related charges tied to certain acquisitions in the fourth quarter.
Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 2026
03:00am, Wednesday, 29'th Oct 2025
INCHEON, Korea--(BUSINESS WIRE)-- #BYOOVIZ--Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis' two oph
Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease
07:30pm, Sunday, 26'th Oct 2025
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease (early AD) who are apolipoprote
Stratos Wealth Partners LTD. Lowers Position in Biogen Inc. $BIIB
04:16am, Sunday, 26'th Oct 2025
Stratos Wealth Partners LTD. trimmed its position in shares of Biogen Inc. (NASDAQ: BIIB) by 15.2% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fu
Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key
11:36am, Friday, 24'th Oct 2025
Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.
Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion
08:30am, Friday, 24'th Oct 2025
Biogen said on Friday it has gained global rights to privately held Vanqua Bio's experimental drug for up to $1.06 billion to expand its pipeline of immunology drugs.
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
07:30am, Friday, 24'th Oct 2025
CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's p
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
07:30am, Wednesday, 22'nd Oct 2025
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming presentations from studies evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L dru
J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround
08:58pm, Sunday, 19'th Oct 2025
Florida-based wealth advisory J. L. Bainbridge & Co. sold 119,376 shares of Biogen (BIIB 0.58%) during the third quarter for an estimated $16.1 million.
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's “Best Inventions of 2025”
07:30pm, Monday, 13'th Oct 2025
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts
